Dr Tamara Milder

Milder T; Stocker S; Baysari M; Day R; Greenfield J, 2022, 'Prescribing of SGLT2 Inhibitors in Clinical Practice: A Qualitative Study of Cardiologists', Heart, Lung and Circulation, vol. 31, pp. S96 - S97, http://dx.doi.org/10.1016/j.hlc.2022.06.117

Tiwary M; Milder TY; Stocker SL; Day RO; Greenfield JR, 2022, 'Sodium-glucose co-transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction', Internal Medicine Journal, http://dx.doi.org/10.1111/imj.15727

MILDER T; STOCKER S; BAYSARI M; DAY RO; GREENFIELD J, 2021, '779-P: Prescribing of SGLT2 Inhibitors in Primary Care: A Qualitative Study of Primary Care Physicians and Endocrinologists', Diabetes, vol. 70, pp. 779 - P, http://dx.doi.org/10.2337/db21-779-p

Milder TY; Stocker SL; Baysari M; Day RO; Greenfield JR, 2021, 'Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists', Diabetes Research and Clinical Practice, vol. 180, pp. 109036, http://dx.doi.org/10.1016/j.diabres.2021.109036

Milder TY; Day RO; Stocker SL; Greenfield JR, 2020, 'Should the cardio-protective properties of sodium-glucose cotransporter 2 inhibitors dictate therapeutic decision-making in patients with type 2 diabetes', Internal Medicine Journal, vol. 50, pp. 645 - 646, http://dx.doi.org/10.1111/imj.14819

Milder TY; Stocker SL; Day RO; Greenfield JR, 2020, 'Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease', Drug Safety, vol. 43, pp. 1211 - 1221, http://dx.doi.org/10.1007/s40264-020-01010-6

2019, 'Book review: Therapeutic Guidelines: Diabetes. Version 1', Australian Prescriber, vol. 42, pp. 205 - 205, http://dx.doi.org/10.18773/austprescr.2019.063

Milder TY; Stocker SL; Samocha-Bonet D; Day RO; Greenfield JR, 2019, 'Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes—cardiovascular and renal benefits in patients with chronic kidney disease', European Journal of Clinical Pharmacology, vol. 75, pp. 1481 - 1490, http://dx.doi.org/10.1007/s00228-019-02732-y

Milder TY; Stocker SL; Shaheed CA; McGrath-Cadell L; Samocha-Bonet D; Greenfield JR; Day RO, 2019, 'Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis', JOURNAL OF CLINICAL MEDICINE, vol. 8, http://dx.doi.org/10.3390/jcm8010045

Milder DA; Milder TY; Kam PCA, 2018, 'Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations', Anaesthesia, vol. 73, pp. 1008 - 1018, http://dx.doi.org/10.1111/anae.14251

Milder T; Lipworth WL; Williams KM; Ritchie JE; Day RO, 2011, '"It looks after me": how older patients make decisions about analgesics for osteoarthritis.', Arthritis Care and Research, vol. 63, pp. 1280 - 1286, http://dx.doi.org/10.1002/acr.20514

Milder TY; Greenfield J; Matthews G; Center J, 2017, 'Hypophosphataemic osteomalacia induced by tenofovir disoproxil fumarate', in CLINICAL ENDOCRINOLOGY, WILEY, AUSTRALIA, Perth, Vol. 89, pp. 70 - 70, presented at Joint Annual Scientific Meetings of Endocrine-Society-of-Australia (ESA) and Society-for-Reproductive-Biology (SRB), AUSTRALIA, Perth, 27 August 2017 - 30 August 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000436537900157&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1